Federal contractor · NEW YORK, NY

GLYPHIC BIOTECHNOLOGIES, INC.

No contract obligations recorded for GLYPHIC BIOTECHNOLOGIES, INC. in FY2026. It also received $1.6M in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
F57WT7JZDH19
Small businessMinority-owned
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 250KFY2024

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for GLYPHIC BIOTECHNOLOGIES, INC. in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

GLYPHIC BIOTECHNOLOGIES, INC. received $1.6M in federal assistance in FY2026, on 1 actions (0 new awards). Its largest program was 93.859 · Biomedical Research and Research Training ($1.6M).

Assistance · FY2026
$1.6M
New awards
0
Actions
1
Since FY2022
$3.2M

Assistance by fiscal year

  1. 409.3KFY2022
  2. 1.2MFY2023
  3. 0FY2024
  4. 0FY2025
  5. 1.6MFY2026

By type

  1. Grants$1.6M100%

Top programs

  1. 93.859 · Biomedical Research and Research Training$1.6M100%

Awarding agencies

  1. National Institutes of Health$1.6M100%
    Department of Health and Human Services

Largest awards

  1. SINGLE-MOLECULE PROTEIN SEQUENCING: RESOLVING INDIVIDUAL AMINO ACIDS VIA COMMERCIALLY ACCESSIBLE NANOPORES - PROJECT SUMMARY THE PREMISE OF…$1.6M
    93.859 · Biomedical Research and Research Training· National Institutes of Health· Project grant· Jul 24, 2026 – Jul 24, 2026· R44GM151897

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2022–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. HERA HEALTH SOLUTIONS INC$250K−100% in FY2026
    FRISCO, TX · 100.0% of this company's obligations are in markets they both serveDefense Health Agency · Scientific research and development services
  2. ACATECHOL, INC$250K−100% in FY2026
    PASADENA, CA · 100% of this company's obligations are in markets they both serveDefense Health Agency · Scientific research and development services
  3. ERIVAN BIO, LLC$250K
    ALACHUA, FL · 100.0% of this company's obligations are in markets they both serveDefense Health Agency · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026.